Safe eradication of large established tumors using neovasculature-targeted TNF-based therapies

ABSTRACT: Systemic toxicities have severely limited the clinical application of Tumor Necrosis Factor (TNF) as an anticancer agent. AcTakines (Activity-on-Target cytokines) are a novel class of immuno-cytokines with improved therapeutic index. A TNF-based AcTakine targeted to CD13 enables selective activation of the tumor neovasculature without any detectable toxicity in vivo. Upregulation of adhesion markers supports enhanced T-cell infiltration leading to control or elimination of solid tumors by respectively CAR T-cells or a combination therapy with CD8-targeted type I Interferon AcTakine. Co-treatment with a CD13-targeted type II Interferon AcTakine leads to very rapid destruction of the tumor neovasculature and complete regression of large, established tumors. As no tumor markers are needed, sa

SUBMITTER: Dr. Leander Huyghe 

PROVIDER: S-SCDT-EMM-2019-11223 | biostudies-other |

REPOSITORIES: biostudies-other